Dilated Cardiomyopathy Drugs in Development, 2022 Market Research Report: Market Landscape, Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

Dilated Cardiomyopathy Drugs in Development, 2022 Market Research Report: Market Landscape, Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com




Dilated Cardiomyopathy Drugs in Development, 2022 Market Research Report: Market Landscape, Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dilated Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 4, 2, 1, 10 and 13 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)

Key Topics Covered:

Introduction

Report Coverage

Overview

Therapeutics Development

  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Companies Involved in Therapeutics Development

  • Avery Therapeutics Inc
  • Berlin Cures Holding AG
  • BioMarin Pharmaceutical Inc
  • BridgeBio Pharma Inc
  • Bristol-Myers Squibb Co
  • Cardior Pharmaceuticals GmbH
  • Celixir Ltd
  • CellServe GmbH
  • DiNAQOR AG
  • Dynomics Inc
  • Heartseed Inc
  • Help Therapeutics
  • iHeart Japan Corp
  • Martin Pharmaceuticals Inc
  • Maze Therapeutics Inc
  • NeoProgen Inc
  • Nuevocor Pte Ltd
  • Olagenesis Corp
  • Pfizer Inc
  • Recursion Pharmaceuticals Inc
  • Renovacor Inc
  • Shionogi & Co Ltd
  • Tenaya Therapeutics Inc

Drug Profiles

  • BC-007 – Drug Profile
  • CDR-426D – Drug Profile
  • Cell Therapy for Dilated Cardiomyopathy – Drug Profile
  • danicamtiv – Drug Profile
  • DINA-005 – Drug Profile
  • DINA-006 – Drug Profile
  • DINA-008 – Drug Profile
  • DINA-009 – Drug Profile
  • DINA-010 – Drug Profile
  • DINA-011 – Drug Profile
  • DYN-101 – Drug Profile
  • emprumapimod – Drug Profile
  • Gene Therapy for Dilated Cardiomyopathy – Drug Profile
  • Gene Therapy for Dilated Cardiomyopathy – Drug Profile
  • Gene Therapy for Dilated Cardiomyopathy – Drug Profile
  • Gene Therapy for Dilated Cardiomyopathy and Heart Failure – Drug Profile
  • Gene Therapy to Activate BAG3 for Dilated Cardiomyopathy – Drug Profile
  • Heartcel – Drug Profile
  • HS-001 – Drug Profile
  • IHJ-301 – Drug Profile
  • MyCardia – Drug Profile
  • Neo-2001 – Drug Profile
  • NovoCardia – Drug Profile
  • redasemtide trifluoroacetate – Drug Profile
  • REN-001 – Drug Profile
  • Small Molecule for Dilated Cardiomyopathy – Drug Profile
  • Small Molecules for Dilated Cardiomyopathy – Drug Profile
  • Small Molecules for Dilated Cardiomyopathy – Drug Profile
  • Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy – Drug Profile
  • TN-301 – Drug Profile
  • trimetazidine – Drug Profile
  • YS-1402 – Drug Profile

Dormant Projects

Product Development Milestones

Featured News & Press Releases

  • Jul 13, 2021: Tenaya Therapeutics unveils preclinical research supporting product candidate for rare and prevalent heart disease indications at ESC Heart Failure 2021
  • Sep 09, 2020: MyoKardia doses first patient in phase 2 clinical trial of danicamtiv in genetic dilated cardiomyopathy
  • Mar 26, 2020: MyoKardia Provides clinical trial update on Danicamtiv study
  • Oct 28, 2019: MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population
  • May 30, 2019: MyoKardia’s MYK-491 shows favourable profile in Phase Ia study
  • Apr 15, 2019: Berlin Cures announces start of Phase IIa for its DNA-based neutralizer of ?1-adrenoceptor autoantibodies
  • Dec 11, 2018: MyoKardia reports positive data from phase 1b single-ascending dose clinical trial of MYK-491 in dilated cardiomyopathy and systolic heart failure patients
  • Dec 06, 2018: Berlin Cures steering committee is assembled to facilitate the design and implementation of phase 2 study of BC 007
  • Oct 30, 2018: MyoKardia Shares Data from new research program ACT-1 at 2018 R&D Day
  • Feb 26, 2018: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study
  • Feb 14, 2018: MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
  • Nov 02, 2017: MyoKardia Provides Update on MYK-491
  • Sep 27, 2017: MyoKardia Provides Update on MYK-491 Clinical Progress
  • Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
  • Dec 02, 2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/y3v930

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900